BOSTON, April 01, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...
The once-large pool of candidates hoping to unseat U.S. House Rep. Lauren Boebert in the 3rd Congressional District was nearly halved this week after five Democratic candidates failed to qualify for ...
Last week, readers heard from the Democratic candidates for the Third Congressional District (CD3) race. Now, it’s time to hear from the Republican incumbent, Representative Lauren Boebert, and GOP ...
Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...
ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...
Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results